These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29555260)

  • 1. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.
    Pranzatelli MR; Allison TJ; Tate ED
    Eur J Paediatr Neurol; 2018 Jul; 22(4):586-594. PubMed ID: 29555260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
    Pranzatelli MR; Tate ED
    Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
    Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
    Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
    Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Colliver JA; Ness JM; Ransohoff RM
    J Neuroinflammation; 2013 Jan; 10():10. PubMed ID: 23324534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED
    Brain Dev; 2016 May; 38(5):439-48. PubMed ID: 26786246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
    J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Mercaptopurine modifies cerebrospinal fluid T cell abnormalities in paediatric opsoclonus-myoclonus as steroid sparer.
    Pranzatelli MR; Tate ED; Allison TJ
    Clin Exp Immunol; 2017 Nov; 190(2):217-225. PubMed ID: 28710878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.
    Pranzatelli MR; Tate ED; McGee NR; MacArthur CA
    Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
    Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus.
    Pranzatelli MR; Tate ED; Travelstead AL; Colliver JA
    J Clin Immunol; 2010 Jan; 30(1):106-13. PubMed ID: 19838774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.
    Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Ransohoff RM; Ness JM; Colliver JA
    J Neuroimmunol; 2012 Feb; 243(1-2):81-8. PubMed ID: 22264765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS.
    Pranzatelli MR; McGee NR; Tate ED
    J Neuroimmunol; 2018 Aug; 321():150-156. PubMed ID: 29685330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Verhulst SJ; Ransohoff RM
    Clin Exp Immunol; 2013 Jun; 172(3):427-36. PubMed ID: 23600831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy ("RITE-CI") for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations.
    Pranzatelli MR; Tate ED; Alber M; Awadalla M; Blumkin L; Lina ES; Leiz S; Móser J
    Neuropediatrics; 2018 Apr; 49(2):123-134. PubMed ID: 29258131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders.
    Pranzatelli MR; Tate ED; McGee NR; Colliver JA
    J Neurol Sci; 2013 Mar; 326(1-2):53-8. PubMed ID: 23380454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.
    Pranzatelli MR; Travelstead AL; Tate ED; Allison TJ; Moticka EJ; Franz DN; Nigro MA; Parke JT; Stumpf DA; Verhulst SJ
    Neurology; 2004 May; 62(9):1526-32. PubMed ID: 15136676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
    J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid γδ T cell frequency is age-related: a case-control study of 435 children with inflammatory and non-inflammatory neurological disorders.
    Pranzatelli MR; Allison TJ; McGee NR; Tate ED
    Clin Exp Immunol; 2018 Jul; 193(1):103-112. PubMed ID: 29485697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Crowley JM; Toennies B; Creer M
    Neuropediatrics; 2008 Jun; 39(3):164-71. PubMed ID: 18991196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
    Pranzatelli MR; Travelstead AL; Tate ED; Allison TJ; Verhulst SJ
    Mov Disord; 2004 Jul; 19(7):770-777. PubMed ID: 15254934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.